Do you want to learn more about identifying external funding opportunities? See ECOR’s website for information on the funding opps database, Pivot or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.
• At the start of the grant term on Nov. 1, 2020, applicants must: hold a tenure-eligible appointment (or equivalent, if institution does not follow a tenure system) at the rank of assistant professor; have held an assistant professor appointment for less than three years (appointed on or after Nov. 1, 2017); and work at an academic, medical, or research institution anywhere in the world.
• If eligibility is based on a future position, the position must be confirmed at the time of submission, and CANNOT be contingent upon receiving this grant.
• Applicants must be AACR members. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Active membership by the application deadline.
• Any individual who currently holds an active AACR grant may not apply.

Citizenship: Unrestricted

Award Amount: $450,000 paid over 3 years
Indirect Costs: None
LOI Deadline: May 26, 2020
Website: https://www.aacr.org/professionals/research-funding/current-funding-opportunities/

2. Triological Society/American College of Surgeons Clinical Scientist Development Awards, American Laryngological, Rhinological, and Otological Society, Inc. (Triological Society)
TRIO and the American College of Surgeon’s (ACS) combined competitive research career development program provides supplemental funding to otolaryngologist-head and neck surgeons who receive NIH Mentored Clinical Scientist Development Awards (K08) or Mentored Patient-Oriented Research Development Awards (K23).

The TRIO and ACS are offering these awards as a means to facilitate the research career development of otolaryngologist-head and neck surgeons, with the expectation that awardees will have sufficient pilot data to submit a competitive R01 proposal prior to the conclusion of the K awards.

Eligibility requirements (partial list):
• Applicants must be MD otolaryngologist-head and neck surgeons and members of the American College of Surgeons.

Citizenship: United States

Award Amount:
• The award may provide three to five consecutive 12-month awards. At least 75 percent of the recipient’s full-time professional effort must be devoted to the program and the remainder devoted to other clinical and teaching pursuits consistent with the objectives of the award.
• The TRIO and ACS will provide salary and fringe benefits for the NIH K08/K23 recipient. A combined total of $80,000 per year in direct costs will be awarded to the institution of the awardee.

Indirect Costs: None
Application Deadline: May 22, 2020
Website: http://www.triological.org/researchgrants.html#trioacs

3. Science and Technology Awards, CooperVision New
The goal of the Science and Technology Award Program is to bring award recipients and CooperVision scientists together to explore new areas of technology advancement. Proposals should demonstrate significant potential for research discoveries within CooperVision key focus areas for 2020. We recognize and highly value the need to find the best ideas that have the potential to deliver benefits to people across the globe.

The key focus areas for 2020 are:
1. Technologies to enhance the optical functionality of contact lenses for the correction of Presbyopia
2. Strategies and Interventions to Slow Myopia Progression; with emphasis on:
   a. New technologies for treatment and management of myopia progression
   b. Myopia control solutions that are effective for fast progressors
   c. Understanding environmental variables/factors that may initiate and prolong myopia progression
   d. Intelligent systems and big data approaches for identifying eyes at risk of developing myopia

Award Types:
• CooperVision Seedling Award: Intended for investigation of early stage concepts
• CooperVision Translational Research Award: For substantive projects intended to incentivize collaboration with CooperVision in new research areas.

Eligibility requirements (partial list):
• Any researcher with Principal Investigator (PI) status holding a MD, OD, or PhD is eligible to apply.
• Applicants, such as postdoctoral fellows, with a waiver of PI status must submit appropriate documentation before funding can be received.

Citizenship: Unspecified

Award Amount:
• CooperVision Seedling Award: $100,000 for 1 year
• CooperVision Translational Research Award: $400,000 paid over 2 years
Indirect Costs: Unspecified
LOI Deadline: May 31, 2020
(Invited) Full Proposal Deadline: Jul 31, 2020

4. Rising Star Research Awards, One Mind Institute (formerly IMHRO)
The goal of the Rising Star Research Awards is to recognize and fund promising, early career investigators through a competitive grants process to accelerate research on major neuropsychiatric disorders.

Proposals for a Rising Star Research Award that are directed at understanding fundamental characteristics and biological mechanisms of brain function and dysfunction are within scope, as well as the translation of basic science mechanisms into better diagnostics and treatments for neuropsychiatric disorders. Note that proposals on schizophrenia research are of particular interest.

Eligibility requirements (partial list):
- To qualify as an early career investigator, candidates should be within 10 years of their initial independent appointment.

Citizenship: United States

Award Amount: $250,000 paid over 3 years
Indirect Costs: 10%
Application Deadline: May 13, 2020
Website: [https://onemind.org/guiding-focus/rising-star-awards/](https://onemind.org/guiding-focus/rising-star-awards/)

5. Greater Value Portfolio, Patrick and Catherine Weldon Donaghue Medical Research Foundation
The goal of this program is to test approaches and tools that organizations can readily use to improve the value of the healthcare they provide to their patients and communities.

We believe value in healthcare is achieved with uniformly high quality outcomes and favorable patient experience for the money we spend. Symptoms of poor healthcare value include:
- high and rising healthcare costs,
- unwarranted variation in prices,
- unaffordable cost of care burden on patients and families,
- unacceptable variation in quality, and
- lack of transparency in both price and outcomes.

Investigators conducting research to develop actionable solutions to one or more of these symptoms of low value healthcare are encouraged to apply to the Greater Value Portfolio program.
Eligible topics include studies that focus on improving value through promising strategies using one or more of these approaches:

- Test models of care, coverage or system change that seek to improve value by addressing one or more of the symptoms of low value
- Reduce routine treatments, tests, and screenings for patients for whom the potential harms (including financial harm) outweigh potential benefits
- Provide tools to help consumers make decisions about their healthcare based on value, including the cost of care to patients, in addition to other patient-centered factors
- Promote conversations between patients and their clinicians and care teams about preferences and trade-offs related to alternative treatment options and/or out of pocket cost burden to patients and families
- Test interventions geared to reducing racial and ethnic disparities through the provision of higher value healthcare

Award Amount: $400,000 paid over 2 years
Indirect Costs: 10% on top of the grant award
LOI Deadline: May 11, 2020
(Invited) Application Deadline: Aug 3, 2020
Website: http://donaghue.org/grant-programs/grant-opportunities/

6. A Kids’ Brain Tumor Cure (AKBTC) Research Grant, Pediatric Low Grade Astrocytoma Foundation (PLGA)

A Kids’ Brain Tumor Cure, a national non-profit organization, was founded in 2007 by a group of dedicated parents, physicians and friends to improve the treatment, quality of life, and long-term outlook for children with brain tumors through research, support, education, and advocacy.

The number one priority of A Kids’ Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. Our hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children’s brain tumors.

Proposals related to basic and translational projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

Citizenship: Unrestricted

Award Amount: Award funding is based on size, impact and complexity of project. Funding can be awarded over one, two or three year period.
Indirect Costs: None
LOI Deadline: Continuous
Website: http://akidsbraintumorcure.org/medical-research-on-childhood-brain-tumors/apply-for-a-plga-sponsored-grant/

7. Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis, Pfizer, Inc./Pfizer Global Medical Grants (GMG) New
Amyloidosis is often misdiagnosed. For example, it is estimated that the correct diagnosis of TTR amyloidosis is delayed by years, in part because it is a multisystemic disorder. Our goal is to help accelerate this patient journey by supporting capacity building programs.

We aim to raise awareness and close knowledge gaps to reduce the time it takes for patients to be correctly diagnosed and make treatment more accessible, while supporting the development of a global network of TTR amyloidosis experts. Expanding the community of practice will help decrease the distance patients need to travel to be diagnosed, although valuable guidance may still be obtained from experienced centers further from home.
Citizenship: Unrestricted

Award Amount: Total funding available for this RFP is $1 million. We anticipate funding between 5-8 projects.
Indirect Costs: 28%
LOI Deadline: Apr 23, 2020

8. Virtual Programs in Moderate-to-Severe Atopic Dermatitis for Dermatologists and Allergists, Pfizer, Inc./Pfizer Global Medical Grants (GMG) New
Considering the disruptions caused by the COVID-19 global pandemic, there is a critical need to maintain the uninterrupted development and distribution of continuing education for healthcare providers. In atopic dermatitis, drug development and management strategies continue to rapidly advance. Given the recent and anticipated cancelation of many medical conferences, healthcare providers will have difficulty staying current with the new emerging data for advanced therapies under development for moderate-to-severe atopic dermatitis.

Through this RFP, it is our intent to support virtual programs for dermatologists & allergists on new emerging therapies for moderate-to-severe atopic dermatitis. Programs targeted towards reviewing data from canceled dermatology or allergy medical conferences are of particular interest.

Citizenship: United States

Award Amount: $250,000 paid over 2 years
Indirect Costs: 28%
Application Deadline: Apr 16, 2020
Website: https://www.pfizer.com/content/clinical-areas